Update on Chronic Lung Allograft Dysfunction
- 393 Downloads
Chronic lung allograft dysfunction (CLAD) encompasses a range of pathologies that cause a transplanted lung to not achieve or maintain normal function. CLAD manifests as airflow restriction and/or obstruction and is predominantly a result of chronic rejection. Three distinct phenotypes of chronic rejection are now recognized: bronchiolitis obliterans, neutrophilic reversible allograft dysfunction, and restrictive allograft syndrome. Recent investigations have revealed that each phenotype has a unique pathology and histopathological findings, suggesting that treatment regimens should be tailored to the underlying etiology. CLAD is poorly responsive to treatment once diagnosed, and therefore, the prevention of the factors that predispose a patient to develop CLAD is critically important. Small and large animal models have contributed significantly to our understanding of CLAD, and more studies are needed to develop treatment regimens that are effective in humans.
KeywordsChronic lung allograft dysfunction Bronchiolitis obliterans Bronchiolitis obliterans syndrome Azithromycin responsive allograft dysfunction Neutrophilic reversible allograft dysfunction Restrictive allograft syndrome
Compliance with Ethical Standards
Conflict of Interest
Daniel Kreisel reports a patent (“Induction in tolerance of lung allograft transplantation”) issued to Washington University.
Jason Gauthier and Ramsey Hachem declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of Particular Interest, Published recently, Have Been Highlighted as: • of Importance •• of Major Importance
- 8••.Verleden SE, Vos R, Mertens V, et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant. 2011;30(6):667–73 .The realization that patients responsive to AZT have a different pathology than AZT non-responders paved the way for the modern understanding of NRAD CrossRefPubMedGoogle Scholar
- 16.Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol. 2003;64(5):521–9.CrossRefPubMedGoogle Scholar
- 19.Angaswamy N, Saini D, Ramachandran S, et al. Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain a and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol. 2010;71(6):560–5.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Ius F, Sommer W, Kieneke D, et al. IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. Transplantation. 2015.Google Scholar
- 33••.Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011;30(7):735–42 .The discovery of RAS has opened a new door for research in the field of lung transplant immunology. This paper was the first to show that RAS is a form of CLAD distinctly different from BO and NRAD, which has prompted investigation into the underlying etiology of this disease CrossRefPubMedGoogle Scholar
- 35•.Vos R, Verleden SE, Ruttens D, et al. Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant. 2013;13(11):3035–40 .This paper reports the case of a patient with RAS who had marked clinical and radiographic improvement after treatment with pirfenidone, which has previously been successful in treating IPF CrossRefPubMedGoogle Scholar
- 41•.Ruttens D, Verleden SE, Vandermeulen E, et al. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am J Transplant. 2016;16(1):254–61 .This study showed that prophylactic AZT reduces the prevalence of CLAD and improves CLAD-free survival, suggesting that there may be a role for prophylactic AZT in all lung transplant patients CrossRefPubMedGoogle Scholar
- 58•.Suzuki H, Lasbury ME, Fan L, et al. Role of complement activation in obliterative bronchiolitis post-lung transplantation. J Immunol. 2013;191(8):4431–9 .Elucidating the role of IL-17 and the complement cascade in the development of BO may lead to new targeted therapies in humans CrossRefPubMedGoogle Scholar